AlphaQuest LLC Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

AlphaQuest LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 219.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,614 shares of the medical research company’s stock after buying an additional 4,544 shares during the quarter. AlphaQuest LLC’s holdings in IQVIA were worth $1,300,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Raymond James Financial Inc. purchased a new stake in shares of IQVIA in the 4th quarter worth about $236,120,000. FMR LLC grew its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in IQVIA during the 3rd quarter valued at about $147,683,000. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on IQV shares. Barclays cut their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Truist Financial restated a “buy” rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, Citigroup lowered their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

NYSE IQV opened at $191.69 on Monday. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $261.72. The stock has a market cap of $33.80 billion, a price-to-earnings ratio of 25.56, a PEG ratio of 1.99 and a beta of 1.50. The company’s 50 day moving average is $197.79 and its two-hundred day moving average is $212.63. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.